A new ophthalmic-only pharma company was formed when Nevakar spun off its pipeline of ocular drugs.
Navneet Puri, PhD, founder, chairman, and CEO of newly formed Vyluma discusses why Nevakar chose to make the move to ophthalmic-only pharma.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.